Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.

appendicitis appendix intestinal ultrasound ulcerative colitis

Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
01 2023
Historique:
revised: 05 07 2022
received: 26 05 2022
accepted: 11 10 2022
pubmed: 3 11 2022
medline: 15 12 2022
entrez: 2 11 2022
Statut: ppublish

Résumé

Increasing evidence suggests that appendicectomy as alternative treatment for ulcerative colitis (UC), especially in patients with histopathological appendiceal inflammation. Intestinal ultrasound (IUS) is a non-invasive diagnostic modality to characterise appendiceal inflammation. To assess appendiceal IUS characteristics in UC patients and compare findings to healthy controls (HC). In this prospective study, appendiceal IUS was performed in consecutive UC patients with active (A; n = 35) or quiescent (Q; n = 30) disease and in HC (n = 30). Transverse appendiceal diameter (TAD) and additional IUS parameters (bowel wall thickness, submucosal layer thickness and colour Doppler signal) were assessed. The appendix was visualised in 41/65 UC patients (63.1%; A vs. Q: 23/35 vs. 18/30, p = 0.67) and 18/30 (60%) HC. UC patients had a higher TAD (A: 5.5 mm, Q: 5.0 mm, HC: 4.3 mm; A-HC p < 0.01; Q-HC p = 0.01, A-Q p = ns) and submucosal layer thickness (A: 1.0 mm, Q: 1.0 mm, HC: 0.7 mm; A-HC p < 0.01, Q-HC: p = 0.01, A-Q: p = ns) when compared to HC. A TAD ≥6 mm corresponding to an ultrasonographic suspicion of acute appendicitis was mainly reported in A-UC patients (A: 43%; Q: 6%; HC: 0%, p = 0.01) and occurred irrespective of disease extent. However, none of the patients had a clinical suspicion of acute appendicitis. A TAD ≥6 mm was predominantly seen in A-UC. TAD was higher in UC patients compared to HC irrespective of disease activity and was characterised by an increased submucosal layer thickness. IUS therefore has the potential to identify UC patients with appendiceal inflammation.

Sections du résumé

BACKGROUND
Increasing evidence suggests that appendicectomy as alternative treatment for ulcerative colitis (UC), especially in patients with histopathological appendiceal inflammation. Intestinal ultrasound (IUS) is a non-invasive diagnostic modality to characterise appendiceal inflammation.
AIMS
To assess appendiceal IUS characteristics in UC patients and compare findings to healthy controls (HC).
METHODS
In this prospective study, appendiceal IUS was performed in consecutive UC patients with active (A; n = 35) or quiescent (Q; n = 30) disease and in HC (n = 30). Transverse appendiceal diameter (TAD) and additional IUS parameters (bowel wall thickness, submucosal layer thickness and colour Doppler signal) were assessed.
RESULTS
The appendix was visualised in 41/65 UC patients (63.1%; A vs. Q: 23/35 vs. 18/30, p = 0.67) and 18/30 (60%) HC. UC patients had a higher TAD (A: 5.5 mm, Q: 5.0 mm, HC: 4.3 mm; A-HC p < 0.01; Q-HC p = 0.01, A-Q p = ns) and submucosal layer thickness (A: 1.0 mm, Q: 1.0 mm, HC: 0.7 mm; A-HC p < 0.01, Q-HC: p = 0.01, A-Q: p = ns) when compared to HC. A TAD ≥6 mm corresponding to an ultrasonographic suspicion of acute appendicitis was mainly reported in A-UC patients (A: 43%; Q: 6%; HC: 0%, p = 0.01) and occurred irrespective of disease extent. However, none of the patients had a clinical suspicion of acute appendicitis.
CONCLUSION
A TAD ≥6 mm was predominantly seen in A-UC. TAD was higher in UC patients compared to HC irrespective of disease activity and was characterised by an increased submucosal layer thickness. IUS therefore has the potential to identify UC patients with appendiceal inflammation.

Identifiants

pubmed: 36320148
doi: 10.1111/apt.17267
pmc: PMC10092200
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-135

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Références

Therap Adv Gastroenterol. 2022 Jun 28;15:17562848221098849
pubmed: 35784194
Dig Dis Sci. 2010 Dec;55(12):3495-501
pubmed: 20936357
Emerg Med J. 2022 Dec;39(12):931-936
pubmed: 35301219
Aliment Pharmacol Ther. 2018 Apr;47(7):922-939
pubmed: 29411405
J Ultrasound Med. 2007 Jan;26(1):37-43; quiz 45-6
pubmed: 17182707
J Crohns Colitis. 2021 Aug 2;15(8):1284-1290
pubmed: 33420784
Scand J Gastroenterol. 2002 Feb;37(2):177-82
pubmed: 11843054
AJR Am J Roentgenol. 1992 Apr;158(4):773-8
pubmed: 1546592
J Exp Med. 1996 Aug 1;184(2):707-15
pubmed: 8760824
N Engl J Med. 2001 Mar 15;344(11):808-14
pubmed: 11248156
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2333-2342
pubmed: 32801008
Chir Ital. 2001 Jan-Feb;53(2):231-8
pubmed: 11396073
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Histopathology. 1998 Aug;33(2):168-73
pubmed: 9762551
Aliment Pharmacol Ther. 2023 Jan;57(1):127-135
pubmed: 36320148
Ultraschall Med. 1997 Jun;18(3):139-42
pubmed: 9340741
Radiology. 1986 Dec;161(3):691-5
pubmed: 3538138
Inflamm Bowel Dis. 2004 May;10(3):215-9
pubmed: 15290914
J Crohns Colitis. 2020 May 21;14(4):465-479
pubmed: 31562739
N Engl J Med. 1987 Sep 10;317(11):666-9
pubmed: 3306375
Gut. 2020 Sep;69(9):1629-1636
pubmed: 31862811
J Crohns Colitis. 2021 Aug 2;15(8):1264-1271
pubmed: 33411887
J Crohns Colitis. 2018 Nov 28;12(12):1385-1391
pubmed: 30085066
Dig Dis Sci. 2003 Jan;48(1):99-108
pubmed: 12645797
Br J Surg. 2019 Nov;106(12):1697-1704
pubmed: 31393608
J Gastroenterol. 2022 Feb;57(2):82-89
pubmed: 35072789
Inflamm Bowel Dis. 2014 Nov;20(11):2198-206
pubmed: 24892966
J Crohns Colitis. 2019 Feb 01;13(2):165-171
pubmed: 30285094
Ultraschall Med. 2017 Jun;38(3):e1-e15
pubmed: 27604052
Gastroenterology. 2002 May;122(5):1428-41
pubmed: 11984528
Radiology. 2000 May;215(2):337-48
pubmed: 10796905
Int J Surg. 2009 Oct;7(5):451-5
pubmed: 19559106
BMC Surg. 2015 Mar 18;15:30
pubmed: 25887789
Am J Gastroenterol. 2009 Oct;104(10):2476-82
pubmed: 19584834
United European Gastroenterol J. 2021 Dec;9(10):1148-1156
pubmed: 34750986
J Clin Ultrasound. 2021 Oct;49(8):847-859
pubmed: 34184283
AJR Am J Roentgenol. 2018 Sep;211(3):W140-W150
pubmed: 30040469
Gastroenterology. 1994 May;106(5):1251-3
pubmed: 8174886

Auteurs

Maud A Reijntjes (MA)

Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, the Netherlands.

Floris A E de Voogd (FAE)

Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.

Willem A Bemelman (WA)

Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands.
IBD Unit, Gastroenterology and Endoscopy, IRCCS Ospedale san Raffaele and University Vita-Salute San Raffaele Milano, Milano, Italy.

Roel Hompes (R)

Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands.

Geert d'Haens (G)

Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.

Christianne J Buskens (CJ)

Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands.

Krisztina B Gecse (KB)

Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH